Biodegradable Intraocular Implant Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular hypertension and glaucoma often require frequent administration of eye drops, which can be inconvenient and may not provide sustained reduction in intraocular pressure, leading to potential side effects and incomplete pressure regulation.
Innovation Solution
Development of biodegradable intraocular implants comprising a biodegradable polymer material and a therapeutic agent, such as compounds with specific chemical formulas, designed for extended release of a therapeutic agent directly into the eye to reduce intraocular pressure for an extended period without frequent dosing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eye drops containing therapeutically active agents are administered frequently to reduce intraocular pressure, then intraocular pressure can be controlled, but patient convenience deteriorates and side effects increase
Solution Approach 1:
The patent applies preliminary action by pre-loading a sustained-release formulation with therapeutically active agents (such as prostamide compounds) into an intraocular implant device. The implant is prepared in advance with a reservoir or matrix containing the drug, designed to release the agent over an extended period (e.g., 1-3 months) after a single administration. This eliminates the need for frequent patient-administered eye drops, as the implant continuously releases the therapeutic agent to maintain effective intraocular pressure control throughout its duration.
Solution Approach 2:
The patent uses an intraocular implant as an intermediary device between the therapeutic agent and the ocular tissues. The implant serves as a mediator that houses the sustained-release formulation and delivers the therapeutically active agent (such as prostamide) directly to the eye. This intermediary system transforms the administration method from frequent topical drops to a single implantation event, improving patient convenience while maintaining reliable intraocular pressure control through controlled drug release.
2Reliability
If eye drops are administered multiple times daily to treat glaucoma, then intraocular pressure reduction is achieved, but treatment duration becomes limited by dosing frequency
Solution Approach 1:
The patent implements continuity of useful action through a sustained-release formulation embedded in an intraocular implant. The therapeutic agent (such as prostamide compound) is released continuously over an extended period (e.g., 1-3 months) from the implant reservoir or matrix. This continuous release mechanism maintains therapeutic drug levels in the eye without interruption, ensuring reliable intraocular pressure reduction throughout the implant's functional life, eliminating the gaps between doses inherent in frequent eye drop administration.
Solution Approach 2:
The implant is pre-loaded with a sustained-release formulation containing a sufficient quantity of therapeutically active agent to maintain effective drug levels throughout the desired treatment duration (e.g., 1-3 months). The formulation is designed in advance with appropriate release kinetics to ensure continuous therapeutic action without requiring repeat administrations, thereby extending treatment duration from daily to monthly or longer intervals.
3Reliability
If frequent eye drop administration is used to control ocular hypertension, then pressure regulation is maintained, but negative side effects increase
Solution Approach 1:
The intraocular implant acts as an intermediary delivery system that reduces exposure to preservatives and other harmful components found in frequent eye drop formulations. By delivering the therapeutically active agent (such as prostamide) through a single implantation event with sustained release, the system eliminates the need for repeated exposure to drop vehicle components and preservatives, thereby reducing cumulative side effects while maintaining effective pressure regulation.
Solution Approach 2:
The implant is designed as a single-use, disposable device that is implanted once and then gradually releases its therapeutic cargo over time. The biodegradable or non-biodegradable implant structure is intended for single administration, after which it either degrades or is surgically removed after completing its release function. This disposable nature eliminates the recurring exposure to harmful components associated with repeated eye drop administrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The implants provide a sustained, effective reduction in intraocular pressure for 1-6 months or more, reducing the need for frequent eye drop administration and minimizing side effects, while effectively treating glaucoma and other ocular hypertension conditions.
Implementation Method 1
The first polymer is a poly(D,L-lactide) having an ester end group... The implant comprises a biodegradable polymer material and a therapeutic agent associated with the biodegradable polymer material
Implementation Method 2
designed for extended release of a therapeutic agent directly into the eye to reduce intraocular pressure for an extended period
Data Source
AI summary
Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.